Gracell Biotechnologies has seen a 360% increase in its stock price YTD, with a particular boost since AstraZeneca decided to acquire it for USD $1.2 billion.The acquisition price sounds fair, and the...
Source LinkGracell Biotechnologies has seen a 360% increase in its stock price YTD, with a particular boost since AstraZeneca decided to acquire it for USD $1.2 billion.The acquisition price sounds fair, and the...
Source Link
Comments